Yesterday at EHA2026, we presented results of our multi-center study on wAIHA (warm Autoimmune Hemolytic Anemia), a rare autoimmune disease leading to severe anemia.
The study demonstrates what can be achieved when industry leaders, clinical experts, and real-world data specialists join forces.
The congress also showcased exciting clinical and real-world evidence across benign hematological conditions, including immune thrombocytopenia, hemophilia, sickle cell disease, and thalassemia.
It is encouraging to see the growing attention given to these rarer indications which have not necessarily been in the spotlight until recent years.
Another highlight was the fascinating advancement in cutting-edge technologies such as CAR-T and gene therapies.
EHA2026 has been a great opportunity for us to reconnect with clinicians and industry colleagues and discuss their latest needs in integrated evidence generation – both in benign and malignant hematology.
We look forward to continuing these discussions beyond the congress.
// Tina, Alexander, Kelvin and Christina
Seeking to elevate your work with real‑world evidence and advanced analytics?
We’d welcome the opportunity to support you!
#wAIHA
#RealWorldEvidence
#RealWorldData
#Hematology
#IntegratedEvidence
